The use of parnaparin sodium (Fluxum) in the prevention of thromboembolic complications after surgical treatment of fractures associated with high risks of thrombosis

Abstract

A comparative assessment of the effectiveness and clinical safety of thrombosis prevention in the treatment of lower limb bone fractures using low-molecular weight heparins: parnaparin sodium (Fluxum) and enoxaparin sodium. Taking into account the literature data on the significant risk of venous thromboembolic complications, we successfully conduct the thromboprophylaxis in patients with the traumatological and orthopedic profile, including in 2019 using the drug parnaparin sodium (Fluxum, «Alfasigma»). Our own comparative clinical experience has shown that with the convenience of taking enoxaparin sodium and the completeness of the scheme, the prevention of thrombosis with the use of parnaparin sodium shows the tendency to better clinical effectiveness and safety. The choice of anticoagulants in traumatological and orthopedic practice, with obvious ease of use, provides the complete scheme for the prevention of thrombosis. Further research is needed on the routine use of sodium parnaparin in order to prevent thronbosis in the treatment of fractures of various localization.